Hercules Capital is expected to report Q3 2026 revenue of $144.11 million and earnings per share of $0.49, with the stock currently trading at approximately $16.41 relative to an average analyst price target of $19.14.
The primary focus for this report is the sustainability of Net Investment Income (NII) per share and its margin of safety over the recently declared $0.47 quarterly distribution.
Investors are monitoring the impact of increased refinancing costs as older debt is replaced, alongside management's core yield target of 11.8% to 12.0%. While deal flow in life sciences remains a tailwind, credit quality and potential loan prepayments will be critical for maintaining the company's premium valuation.